Ophthalmology Biosimilars Market Estimations (2025 - 2035)
The ophthalmology biosimilars market covers biosimilars of intravitreal anti-VEGF biologics used in eye care, including aflibercept (Eylea 2 mg) and ranibizumab (Lucentis) biosimilars, in vials and prefilled syringes, for neovascular age-related macular degeneration, diabetic macular oedema and diabetic retinopathy, macular oedema after retinal vein occlusion and myopic choroidal neovascularisation, used in retina clinics and hospitals.
📄Report ID:2522
|
📊Format: Databook
|
📅Published: 19 November 2026
|
⚡Delivery: Immediate